• At the end of a successful 2022. Tchaikapharma receives MA for a unique anti-gout drug

    December 6, 2022

    Tchaikapharma’s latest medicinal product to receive marketing authorisation from the Bulgarian Drug Agency is Clopasa (colchicine) 0.5 mg tablets – the first gout treatment in the company’s broad portfolio.


    Clopasa belongs to the group of medicines with antipathic action. It is used for the treatment of acute attacks of gout, in the condition of chronic gout, for the prevention of acute attacks when starting treatment with other drugs lowering uric acid in the blood and urine or when treating periodic diseases (Familial Mediterranean Fever).


    The medicinal product is available on prescription.
    ATC code: M04AC01